Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 12 | 2020 | 102 | 4.620 |
Why?
|
| Dermatologic Agents | 7 | 2020 | 229 | 2.560 |
Why?
|
| Skin Neoplasms | 4 | 2019 | 214 | 1.830 |
Why?
|
| Myoclonic Epilepsies, Progressive | 2 | 2018 | 2 | 1.290 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 2 | 2018 | 5 | 1.290 |
Why?
|
| Epidermis | 2 | 2018 | 30 | 1.280 |
Why?
|
| Dermatology | 3 | 2019 | 163 | 1.190 |
Why?
|
| Scabies | 2 | 2017 | 2 | 1.180 |
Why?
|
| Psoriasis | 3 | 2020 | 360 | 1.160 |
Why?
|
| Humans | 47 | 2020 | 31836 | 1.130 |
Why?
|
| Syphilis, Congenital | 2 | 2017 | 3 | 1.030 |
Why?
|
| Biological Products | 5 | 2020 | 77 | 1.000 |
Why?
|
| Boron Compounds | 3 | 2020 | 11 | 0.990 |
Why?
|
| Skin | 4 | 2020 | 210 | 0.910 |
Why?
|
| Eczema | 3 | 2019 | 13 | 0.850 |
Why?
|
| Drugs, Investigational | 2 | 2020 | 6 | 0.830 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 244 | 0.830 |
Why?
|
| Lafora Disease | 2 | 2018 | 2 | 0.810 |
Why?
|
| Drug Eruptions | 1 | 2020 | 9 | 0.730 |
Why?
|
| Antiparasitic Agents | 2 | 2017 | 6 | 0.730 |
Why?
|
| Skin Diseases | 2 | 2019 | 142 | 0.720 |
Why?
|
| Students, Health Occupations | 1 | 2020 | 8 | 0.700 |
Why?
|
| Herpes Zoster | 1 | 2019 | 10 | 0.700 |
Why?
|
| Problem-Based Learning | 1 | 2020 | 28 | 0.690 |
Why?
|
| Neck | 1 | 2019 | 27 | 0.690 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 48 | 0.690 |
Why?
|
| Leukemia | 1 | 2019 | 40 | 0.680 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 21 | 0.680 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2019 | 26 | 0.670 |
Why?
|
| Heart Transplantation | 1 | 2019 | 26 | 0.670 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 58 | 0.660 |
Why?
|
| Eosinophilia | 1 | 2019 | 12 | 0.660 |
Why?
|
| Erythrocytes | 1 | 2018 | 45 | 0.640 |
Why?
|
| Pruritus | 2 | 2020 | 47 | 0.630 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 3 | 0.610 |
Why?
|
| Melanoma | 1 | 2019 | 164 | 0.600 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 154 | 0.600 |
Why?
|
| Child | 9 | 2020 | 2425 | 0.600 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 38 | 0.590 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 17 | 0.590 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2016 | 8 | 0.570 |
Why?
|
| Adult | 13 | 2020 | 9327 | 0.570 |
Why?
|
| Female | 17 | 2020 | 19859 | 0.530 |
Why?
|
| Referral and Consultation | 1 | 2016 | 140 | 0.510 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 518 | 0.510 |
Why?
|
| Adolescent | 7 | 2020 | 3511 | 0.510 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2015 | 9 | 0.500 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2015 | 12 | 0.500 |
Why?
|
| Male | 15 | 2020 | 19091 | 0.480 |
Why?
|
| Infant | 4 | 2019 | 1055 | 0.470 |
Why?
|
| Administration, Cutaneous | 4 | 2019 | 116 | 0.470 |
Why?
|
| Dermatomyositis | 2 | 2016 | 19 | 0.450 |
Why?
|
| Administration, Oral | 3 | 2018 | 181 | 0.440 |
Why?
|
| Blister | 1 | 2012 | 7 | 0.430 |
Why?
|
| Extremities | 1 | 2012 | 51 | 0.420 |
Why?
|
| Livedo Reticularis | 1 | 2012 | 2 | 0.420 |
Why?
|
| Indans | 1 | 2012 | 31 | 0.410 |
Why?
|
| Leg | 1 | 2012 | 66 | 0.410 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3488 | 0.400 |
Why?
|
| Biopsy, Needle | 4 | 2019 | 95 | 0.400 |
Why?
|
| Pemphigus | 1 | 2010 | 8 | 0.370 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 531 | 0.360 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 899 | 0.360 |
Why?
|
| Middle Aged | 10 | 2019 | 11824 | 0.350 |
Why?
|
| Diet | 2 | 2013 | 385 | 0.350 |
Why?
|
| Prognosis | 4 | 2018 | 1498 | 0.340 |
Why?
|
| Infant, Newborn | 3 | 2017 | 665 | 0.340 |
Why?
|
| Algorithms | 1 | 2012 | 495 | 0.330 |
Why?
|
| Drug Utilization | 1 | 2008 | 49 | 0.320 |
Why?
|
| Food, Formulated | 1 | 2008 | 12 | 0.310 |
Why?
|
| Aged | 7 | 2020 | 10288 | 0.300 |
Why?
|
| Antipruritics | 2 | 2018 | 4 | 0.300 |
Why?
|
| Deglutition Disorders | 1 | 2008 | 50 | 0.300 |
Why?
|
| Permethrin | 2 | 2017 | 2 | 0.300 |
Why?
|
| Ivermectin | 2 | 2017 | 9 | 0.290 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 3988 | 0.280 |
Why?
|
| Calcitriol | 2 | 2020 | 25 | 0.270 |
Why?
|
| Risk Assessment | 4 | 2019 | 1431 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 300 | 0.260 |
Why?
|
| Hospitalization | 2 | 2018 | 463 | 0.240 |
Why?
|
| Young Adult | 4 | 2019 | 2603 | 0.240 |
Why?
|
| Child, Preschool | 2 | 2019 | 1259 | 0.240 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 127 | 0.230 |
Why?
|
| Quality of Life | 3 | 2019 | 924 | 0.220 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3294 | 0.200 |
Why?
|
| Double-Blind Method | 2 | 2020 | 523 | 0.190 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 4 | 0.190 |
Why?
|
| Aerosols | 1 | 2020 | 14 | 0.190 |
Why?
|
| Biological Therapy | 1 | 2020 | 20 | 0.180 |
Why?
|
| Serum Sickness | 1 | 2020 | 1 | 0.180 |
Why?
|
| Pseudolymphoma | 1 | 2020 | 4 | 0.180 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2020 | 13 | 0.180 |
Why?
|
| Scalp | 1 | 2020 | 38 | 0.180 |
Why?
|
| Granuloma | 1 | 2020 | 14 | 0.180 |
Why?
|
| Azetidines | 1 | 2020 | 10 | 0.180 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2020 | 8 | 0.180 |
Why?
|
| Exanthema | 1 | 2020 | 21 | 0.180 |
Why?
|
| Students, Nursing | 1 | 2020 | 7 | 0.180 |
Why?
|
| Herpesvirus 3, Human | 1 | 2019 | 4 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 284 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2020 | 67 | 0.170 |
Why?
|
| Sweet Syndrome | 1 | 2019 | 6 | 0.170 |
Why?
|
| Nail Diseases | 1 | 2019 | 5 | 0.170 |
Why?
|
| Cellulitis | 1 | 2019 | 10 | 0.170 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2019 | 9 | 0.170 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 22 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 12 | 0.170 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 13 | 0.170 |
Why?
|
| Keratosis | 1 | 2019 | 23 | 0.170 |
Why?
|
| Dermoscopy | 1 | 2019 | 12 | 0.170 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 65 | 0.170 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2019 | 3 | 0.170 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 151 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2019 | 108 | 0.170 |
Why?
|
| Calciphylaxis | 1 | 2018 | 1 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 45 | 0.160 |
Why?
|
| Pediatrics | 1 | 2020 | 157 | 0.160 |
Why?
|
| Public Opinion | 1 | 2018 | 17 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 94 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 124 | 0.160 |
Why?
|
| Drug Design | 1 | 2018 | 43 | 0.160 |
Why?
|
| Acute Disease | 1 | 2019 | 252 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2019 | 49 | 0.160 |
Why?
|
| Pemphigoid Gestationis | 1 | 2018 | 3 | 0.160 |
Why?
|
| Sex Factors | 2 | 2018 | 662 | 0.160 |
Why?
|
| Students, Medical | 1 | 2020 | 129 | 0.150 |
Why?
|
| Drug Approval | 1 | 2017 | 10 | 0.150 |
Why?
|
| Curriculum | 1 | 2020 | 208 | 0.150 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2018 | 24 | 0.150 |
Why?
|
| Penicillins | 1 | 2017 | 9 | 0.150 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 7 | 0.150 |
Why?
|
| Treponema pallidum | 1 | 2017 | 7 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 45 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2019 | 400 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2018 | 147 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 85 | 0.150 |
Why?
|
| Foot | 1 | 2017 | 39 | 0.150 |
Why?
|
| Developing Countries | 1 | 2017 | 48 | 0.150 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2017 | 9 | 0.140 |
Why?
|
| Age Factors | 2 | 2018 | 1187 | 0.140 |
Why?
|
| Microscopy | 1 | 2017 | 26 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2017 | 32 | 0.140 |
Why?
|
| Southeastern United States | 1 | 2017 | 79 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2016 | 81 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2019 | 378 | 0.140 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 44 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2017 | 162 | 0.140 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2016 | 2 | 0.140 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2016 | 5 | 0.140 |
Why?
|
| Disease Progression | 1 | 2018 | 593 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 8 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 297 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2017 | 108 | 0.130 |
Why?
|
| Animals | 2 | 2018 | 7450 | 0.130 |
Why?
|
| Mycophenolic Acid | 2 | 2017 | 40 | 0.130 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 2014 | 6 | 0.120 |
Why?
|
| Prevalence | 1 | 2017 | 979 | 0.120 |
Why?
|
| Psychometrics | 1 | 2015 | 136 | 0.120 |
Why?
|
| Scurvy | 1 | 2013 | 3 | 0.120 |
Why?
|
| Methotrexate | 2 | 2017 | 64 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1192 | 0.110 |
Why?
|
| United States | 2 | 2020 | 3925 | 0.110 |
Why?
|
| North Carolina | 1 | 2016 | 1514 | 0.100 |
Why?
|
| Immunosuppression | 1 | 2012 | 121 | 0.100 |
Why?
|
| Muscle Strength | 1 | 2012 | 159 | 0.100 |
Why?
|
| Parkinson Disease | 1 | 2012 | 82 | 0.100 |
Why?
|
| Remission Induction | 1 | 2010 | 84 | 0.090 |
Why?
|
| Prednisone | 1 | 2010 | 61 | 0.090 |
Why?
|
| Pemphigoid, Bullous | 2 | 2019 | 9 | 0.090 |
Why?
|
| Fever | 2 | 2019 | 61 | 0.080 |
Why?
|
| Nonprescription Drugs | 1 | 2008 | 23 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 564 | 0.080 |
Why?
|
| Barium | 1 | 2008 | 4 | 0.080 |
Why?
|
| Viscosity | 1 | 2008 | 22 | 0.080 |
Why?
|
| Rheology | 1 | 2008 | 30 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 504 | 0.070 |
Why?
|
| Biopsy | 2 | 2018 | 260 | 0.070 |
Why?
|
| Age of Onset | 1 | 2020 | 93 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2020 | 49 | 0.040 |
Why?
|
| Streptococcus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 104 | 0.040 |
Why?
|
| Thigh | 1 | 2019 | 41 | 0.040 |
Why?
|
| Fingers | 1 | 2019 | 64 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 35 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 98 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2018 | 166 | 0.040 |
Why?
|
| Chikungunya virus | 1 | 2017 | 1 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2018 | 117 | 0.040 |
Why?
|
| Pain | 1 | 2020 | 287 | 0.040 |
Why?
|
| Hypopigmentation | 1 | 2017 | 7 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 164 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 161 | 0.040 |
Why?
|
| Skin Pigmentation | 1 | 2017 | 26 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2017 | 57 | 0.030 |
Why?
|
| Neurofibromatosis 2 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neurofibromatosis 1 | 1 | 2016 | 9 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2017 | 147 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2018 | 279 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2017 | 100 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 471 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 994 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2271 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 540 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 145 | 0.030 |
Why?
|